Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Array Technologies Inc ARRY

Industrials
Array Technologies, Inc. is a provider of utility-scale solar tracker technology. The Company manufactures ground-mounting tracking systems used in utility and distributed generation solar energy projects worldwide. The Company’s segments include Array Legacy Operations and STI Legacy Operations. Its principal products are a portfolio of integrated solar tracking systems comprised of software... see more

Recent & Breaking News (NDAQ:ARRY)

Array BioPharma to Present at the 37th Annual J.P. Morgan Healthcare Conference

PR Newswire December 20, 2018

Array BioPharma to Present at the 30th Annual Piper Jaffray Healthcare Conference

PR Newswire November 20, 2018

Array BioPharma to Present at the Stifel 2018 Healthcare Conference and the Jefferies 2018 London Healthcare Conference

PR Newswire November 6, 2018

Analysis: Positioning to Benefit within Array BioPharma, SPX FLOW, Holly Energy Partners, Electro Scientific Industries, Leggett & Platt, and CBL & Associates Properties — Research Highlights Growth, Revenue, and Consolidated Results

GlobeNewswire November 2, 2018

Array BioPharma Reports Financial Results for the First Quarter of Fiscal 2019

PR Newswire October 30, 2018

The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs

Benzinga.com  October 27, 2018

Array BioPharma to Report Financial Results for the First Quarter of Fiscal 2019 on October 30, 2018

PR Newswire October 23, 2018

Array BioPharma to Present at the 2018 Cantor Global Healthcare Conference

PR Newswire September 25, 2018

European Commission Approves BRAFTOVI® (encorafenib) in Combination with MEKTOVI® (binimetinib) for Advanced BRAF-mutant Melanoma

PR Newswire September 20, 2018

Array BioPharma Announces Publication of BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) Phase 3 Overall Survival Data in The Lancet Oncology

PR Newswire September 13, 2018

Array BioPharma to Present at the Wells Fargo Securities 2018 Healthcare Conference

PR Newswire August 30, 2018

Array BioPharma Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2018

PR Newswire August 14, 2018

Array BioPharma Names Carrie S. Cox Chairman of its Board of Directors

PR Newswire August 10, 2018

Array BioPharma to Report Financial Results for the Fourth Quarter and Full Year of Fiscal 2018 on August 14, 2018

PR Newswire August 7, 2018

Array BioPharma Receives FDA Breakthrough Therapy Designation for BRAFTOVI™ in combination with MEKTOVI® and cetuximab for BRAFV600E-mutant Metastatic Colorectal Cancer

PR Newswire August 7, 2018

BRAFTOVI™ (encorafenib) + MEKTOVI® (binimetinib) Receives Positive CHMP Opinion for Advanced BRAF-mutant Melanoma

PR Newswire July 27, 2018

The National Comprehensive Cancer Network (NCCN) Guidelines Recommend BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib) as a Category 1 Treatment Option for Patients with Advanced BRAF-mutant Melanoma

PR Newswire July 13, 2018

Array BioPharma Announces FDA Approval of BRAFTOVI™ (encorafenib) in Combination with MEKTOVI® (binimetinib)

PR Newswire June 27, 2018

Array BioPharma Announces a 62% Observed Overall Survival at One Year from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant CRC at the ESMO 20th World Congress on Gastrointestinal Cancer

PR Newswire June 23, 2018

Array BioPharma to Present Overall Survival Results from the Phase 3 BEACON CRC Safety Lead-In of the Combination of Encorafenib, Binimetinib and Cetuximab in BRAF-Mutant Colorectal Cancer at the ESMO 20th World Congress on Gastrointestinal Cancer

PR Newswire June 18, 2018